Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

French Biotech Adcytherix Secures €105 Million Series A for ADC Development

French Biotech Adcytherix Secures €105 Million Series A for ADC Development

Adcytherix, a French antibody-drug conjugate (ADC) specialist, has successfully closed a €105 million ($122 million) Series A funding round, marking a significant milestone in the company's journey to advance its lead candidate into clinical trials. The investment, led by Bpifrance, positions Adcytherix at the forefront of European ADC development and underscores growing investor confidence in the potential of targeted cancer therapies.

NoahAI News10/16/2025
Dianthus Therapeutics Inks $1 Billion Deal with China's Leads Biolabs for Autoimmune Asset

Dianthus Therapeutics Inks $1 Billion Deal with China's Leads Biolabs for Autoimmune Asset

Dianthus Therapeutics has entered into a licensing agreement with Nanjing Leads Biolabs, offering up to $1 billion for the rights to a novel bispecific antibody targeting autoimmune disorders. The deal marks a significant move in the autoimmune disease space and underscores the growing importance of international collaborations in drug development.

NoahAI News10/16/2025
Merck's Keytruda Achieves Breakthrough in Ovarian Cancer Treatment

Merck's Keytruda Achieves Breakthrough in Ovarian Cancer Treatment

Merck & Co.'s blockbuster drug Keytruda (pembrolizumab) has demonstrated significant progress in the treatment of platinum-resistant recurrent ovarian cancer, marking a potential turning point in the management of this challenging disease.In a landmark phase 3 trial, Keynote-B96, Keytruda has shown a statistically significant overall survival (OS) benefit in patients with platinum-resistant recurrent ovarian cancer, regardless of their PD-L1 expression levels. This achievement represents the first time an immune checkpoint inhibitor-based regimen has demonstrated such broad efficacy in this patient population.

NoahAI News10/16/2025
CommonSpirit's Trinity Health System and UPMC Explore Integration, Signaling Market Expansion

CommonSpirit's Trinity Health System and UPMC Explore Integration, Signaling Market Expansion

In a significant development for the healthcare landscape, CommonSpirit Health's Trinity Health System and UPMC have announced their intention to pursue integration, potentially reshaping regional healthcare delivery and expanding UPMC's market presence.

NoahAI News10/16/2025
Vega Health Launches AI Marketplace for Healthcare Systems

Vega Health Launches AI Marketplace for Healthcare Systems

Vega Health, a new startup founded by physician Mark Sendak, M.D., has emerged from stealth mode with a mission to revolutionize the adoption and implementation of artificial intelligence (AI) in healthcare. Launched with $4 million in seed funding from Bessemer Venture Partners, Vega Health aims to bridge the gap between AI developers and healthcare organizations by offering a curated marketplace of vetted AI models and providing ongoing performance monitoring.

NoahAI News10/16/2025
Biopharma Industry Faces Significant Workforce Restructuring in Q3 2025

Biopharma Industry Faces Significant Workforce Restructuring in Q3 2025

The pharmaceutical industry has witnessed a substantial increase in layoffs during the third quarter of 2025, with major companies implementing large-scale restructuring plans. This surge in workforce reductions represents a significant shift in the industry landscape, driven by cost-cutting measures and strategic realignments.

NoahAI News10/16/2025
AstraZeneca and Immunai Forge $85M Partnership for IBD Target Discovery

AstraZeneca and Immunai Forge $85M Partnership for IBD Target Discovery

AstraZeneca has announced a new collaboration with artificial intelligence company Immunai, valued at up to $85 million, to advance a novel target for inflammatory bowel disease (IBD) therapy. This partnership marks a significant step forward in leveraging AI for drug discovery in the pharmaceutical industry.

NoahAI News10/16/2025
Novo Nordisk's $2.1B Bet on Omeros' Rare Disease Drug Reshapes Complement Therapy Landscape

Novo Nordisk's $2.1B Bet on Omeros' Rare Disease Drug Reshapes Complement Therapy Landscape

In a significant move that underscores the growing importance of complement-mediated therapies, Danish pharmaceutical giant Novo Nordisk has struck a deal worth up to $2.1 billion with biotechnology firm Omeros Corporation. The agreement, announced on Wednesday, centers around zaltenibart, Omeros' promising antibody treatment for rare blood and kidney disorders.

NoahAI News10/16/2025
Lilly's Oral GLP-1 Orforglipron Demonstrates Superiority in Diabetes Trials, Positioning for Market Leadership

Lilly's Oral GLP-1 Orforglipron Demonstrates Superiority in Diabetes Trials, Positioning for Market Leadership

Eli Lilly's experimental oral GLP-1 receptor agonist, orforglipron, has shown promising results in two new Phase 3 trials for type 2 diabetes, reinforcing its potential as a foundational treatment option. The drug outperformed AstraZeneca's Farxiga and placebo in separate studies, marking another milestone in Lilly's ambitious diabetes and obesity treatment program.

NoahAI News10/16/2025
Sarepta Perseveres with Gene Therapy for LGMD Despite Regulatory Hurdles

Sarepta Perseveres with Gene Therapy for LGMD Despite Regulatory Hurdles

Sarepta Therapeutics, a biotech company known for its gene therapy programs, is pushing forward with its investigational treatment for limb-girdle muscular dystrophy (LGMD) despite recent setbacks and a strategic pivot towards siRNA therapeutics. The company presented promising late-stage data for its gene therapy candidate SRP-9003 at the 30th annual International Congress of the World Muscle Society (WMS) in Vienna, Austria, demonstrating the treatment's potential efficacy while navigating complex regulatory challenges.

NoahAI News10/16/2025
Pelage Pharmaceuticals Secures $120 Million for Innovative Hair Loss Treatment

Pelage Pharmaceuticals Secures $120 Million for Innovative Hair Loss Treatment

Pelage Pharmaceuticals has successfully raised $120 million in a Series B financing round to advance its groundbreaking hair loss treatment into Phase III clinical trials. The company's lead molecule, PP405, is a topical small molecule designed to reactivate dormant hair follicle stem cells and stimulate hair growth in patients with androgenetic alopecia.

NoahAI News10/16/2025
Boehringer Ingelheim's ADC Push: Nearly $1B Deal with AimedBio Highlights Busy Year of Partnerships

Boehringer Ingelheim's ADC Push: Nearly $1B Deal with AimedBio Highlights Busy Year of Partnerships

Boehringer Ingelheim, the German pharmaceutical giant, has made a significant move in the antibody-drug conjugate (ADC) space, signing a deal worth up to $991 million with South Korea's AimedBio. This latest partnership, announced on October 15, 2025, underscores Boehringer's aggressive strategy in oncology and adds to a string of substantial collaborations inked by the company throughout the year.

NoahAI News10/16/2025
«1...202122...67»